The stock of Nuvo Pharmaceuticals Inc (TSE:NRI) is a huge mover today! About 112,202 shares traded hands or 380.83% up from the average. Nuvo Pharmaceuticals Inc (TSE:NRI) has risen 4.31% since April 7, 2016 and is uptrending. It has underperformed by 1.84% the S&P500.
The move comes after 8 months negative chart setup for the $62.24M company. It was reported on Nov, 11 by Barchart.com. We have $4.66 PT which if reached, will make TSE:NRI worth $8.71 million less.
More notable recent Nuvo Pharmaceuticals Inc (TSE:NRI) news were published by: Prnewswire.com which released: “Nuvo Pharmaceuticalsâ„¢ Inc. Appoints New Chief Financial Officer” on September 01, 2016, also Prnewswire.com with their article: “Nuvo Pharmaceuticalsâ„¢ Inc. announces appointment of Vice President, Business …” published on April 04, 2016, Prnewswire.com published: “Nuvo Pharmaceuticalsâ„¢ Inc. Announces Pennsaid 2% Phase 3 Trial to Support …” on July 13, 2016. More interesting news about Nuvo Pharmaceuticals Inc (TSE:NRI) were released by: Prnewswire.com and their article: “Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies” published on March 01, 2016 as well as Prnewswire.com‘s news article titled: “Nuvo Pharmaceuticalsâ„¢ Inc. Announces Results from European Ankle Sprain Study …” with publication date: March 07, 2016.
Nuvo Pharmaceuticals Inc., formerly Nuvo Research Inc., is a Canada healthcare company. The company has a market cap of $62.24 million. The Firm offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. It has a 18.15 P/E ratio. The Company’s Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.